A Phase 1, Randomized, Open Label, Partial Crossover Study To Evaluate The Pharmacokinetics And Safety Of Three Age-appropriate Modified Release Formulations And The Immediate Release Solution Of Tofacitinib In Healthy Adult Volunteers
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 11 Jul 2017
At a glance
- Drugs Tofacitinib (Primary)
- Indications Atopic dermatitis; Dermatomyositis; Juvenile rheumatoid arthritis; Plaque psoriasis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 05 Jul 2017 Planned End Date changed from 4 Jan 2018 to 1 Nov 2017.
- 05 Jul 2017 Planned primary completion date changed from 4 Jan 2018 to 1 Nov 2017.
- 05 Jul 2017 Planned initiation date changed from 18 Oct 2017 to 1 Sep 2017.